Partners will advance end-to-end development of biologics for regionally prioritized diseases starting with Mpox and HIV

合作伙伴将从猴痘和艾滋病开始，全面推进区域性优先疾病生物制品的端到端开发。

CAIRO, Egypt, BERLIN, Germany and NEW YORK, U.S., October 10, 2025 / Biotech Newswire / --

埃及开罗、德国柏林和美国纽约，2025年10月10日 /生物科技新闻社/ --

IAVI

国际艾滋病疫苗倡议组织

, a nonprofit scientific research organization, based in New York, U.S.;

，一家位于美国纽约的非营利性科学研究组织；

Minapharm

米纳制药

, the largest biosimilars manufacturer in Africa, based in Cairo, Egypt; and

，非洲最大的生物仿制药制造商，总部位于埃及开罗；以及

ProBioGen

普罗比奥根

, a recognized leader in contract development and manufacturing, and a trusted technology provider based in Berlin, Germany today announced a strategic partnership to advance the end-to-end development and manufacturing of priority vaccines and biologics in Africa.

，一家在合同开发和制造领域公认的领导者，同时也是总部位于德国柏林的可信赖技术供应商，今天宣布了一项战略合作伙伴关系，旨在推动非洲优先疫苗和生物制品的端到端开发和制造。

With only one percent of the vaccines serving the African market produced on the continent, there is a pressing need to strengthen innovation and expand local manufacturing capacities to better meet the region's health challenges. Through a novel public-private partnership, these three organizations will work together to bolster the innovation ecosystem on the continent and enable sustainable access to urgently-needed products..

仅有百分之一的非洲市场疫苗是在非洲大陆生产的，因此迫切需要加强创新并扩大本地生产能力，以更好地应对该地区的健康挑战。通过一种新颖的公私合作伙伴关系，这三家组织将共同努力加强非洲大陆的创新生态系统，并确保可持续获得急需的产品。

Combining Minapharm's 25 year proven track record in manufacturing and commercializing high-quality, innovative yet affordable biologics on the African continent; ProBioGen's vaccine vector, avian cell line and manufacturing technologies; and IAVI's end-to-end product development expertise, the partners will leverage their complementary strengths to accelerate the development of ProBioGen's Modified Vaccinia Ankara as a vaccine against Mpox.

结合米纳制药在非洲大陆制造和销售高质量、创新且价格合理的生物制品方面25年的成功记录；ProBioGen的疫苗载体、禽类细胞系和制造技术；以及IAVI的端到端产品开发专业知识，合作伙伴将利用他们互补的优势，加速ProBioGen的改良型安卡拉痘苗作为Mpox疫苗的开发进程。

The vaccine is being optimized for manufacturing productivity, immunogenicity, and ease of delivery, with the aim of overcoming cost, supply, and implementation barriers that have severely restricted access in regions most impacted by recent Mpox outbreaks..

该疫苗正在为提高生产效率、免疫原性和递送便利性进行优化，目的是克服成本、供应和实施障碍，这些障碍严重限制了受最近Mpox疫情影响最严重地区的获取途径。

Building on Minapharm's established monoclonal antibody (mAb) production capabilities and IAVI's history of partnership to support local manufacturing, the three organizations will join forces to further expand the existing regional manufacturing hub for affordable mAbs. The partnership relies on IAVI's strong collaboration with the Africa Centres for Disease Control and Prevention; the Wellcome Trust, who is providing support through grant 226431/Z/22/Z; and other partners.

基于Minapharm现有的单克隆抗体（mAb）生产能力以及IAVI支持本地制造的合作历史，这三家机构将携手进一步扩展现有的区域性低成本单抗生产中心。该合作依托IAVI与非洲疾病控制和预防中心的紧密协作、惠康信托通过拨款226431/Z/22/Z提供的支持，以及其他合作伙伴的力量。

This initiative will be enabled through technology transfer of IAVI's portfolio of antibody-based products for HIV prevention, combined with joint capacity-strengthening, market-shaping efforts, and future collaborations to expand access to a broader range of monoclonal and multispecific antibodies.

这一举措将通过转让IAVI基于抗体的HIV预防产品组合的技术实现，并结合联合能力建设、市场塑造努力以及未来合作，以扩大获取更广泛单克隆和多特异性抗体的机会。

By expanding regionally driven innovation and supply for priority products, this partnership— which has been convened with support by the kENUP Africa Foundation -- will strengthen health security, bolster production capacity, and enable rapid response capabilities to address leading infectious diseases at their source..

通过扩大区域驱动的创新和重点产品的供应，这一在kENUP非洲基金会支持下召集的合作伙伴关系将加强卫生安全、提升生产能力，并实现快速响应能力，以从源头上应对主要的传染病。

'We are thrilled to launch this new partnership with Minapharm and ProBioGen, which represents a potentially transformative opportunity to accelerate the development of urgently needed innovations to address diseases with devastating and disproportionate impact in Africa,'

“我们非常高兴与Minapharm和ProBioGen达成这一新的合作伙伴关系，这代表了一个可能带来变革的机会，可以加速开发急需的创新成果，以应对那些在非洲具有毁灭性和不成比例影响的疾病。”

said Mark Feinberg, M.D., Ph.D., IAVI's President and CEO.

马克·芬恩伯格 (Mark Feinberg) 医学博士、哲学博士，IAVI 总裁兼首席执行官表示。

'This pioneering collaboration will ensure access to cutting-edge innovations like antibodies for HIV prevention and innovative vaccine strategies for emerging infectious diseases such as Mpox – by expanding the capacity to research, develop, and produce those products in the region where they are most needed.'.

“这一开创性的合作将确保获得前沿的创新成果，例如用于预防艾滋病的抗体和针对诸如猴痘等新兴传染病的创新疫苗策略——通过扩大在最需要这些产品的地方研究、开发和生产这些产品的能力。”

'By combining our decades of expertise in end-to-end biomanufacturing on the continent, with ProBioGen's bioprocessing excellence, and IAVI's strong global product development leadership, we are creating an intercontinental scientific platform to scale innovation and ensure equitable access to innovative therapies and vaccines for Africa,' .

“通过结合我们在非洲大陆端到端生物制造领域数十年的专业知识，ProBioGen的生物处理卓越能力，以及IAVI强大的全球产品开发领导力，我们正在创建一个跨洲科学平台，以扩大创新规模，并确保非洲能够公平获取创新疗法和疫苗。”

said Dr. Shaheer Bardissi, Ph.D., Co-CEO, Minapharm Pharmaceuticals.

沙希尔·巴迪西博士，Minapharm制药公司联合首席执行官表示。

'It has always been our vision to enable access to complex biologics in the MEA region while strengthening regional and local manufacturing capabilities. We are proud to contribute our expertise as well as our vaccine and antibody manufacturing technologies to this alliance and to support exactly where it matters most,'.

“我们一直致力于在中东和非洲地区实现对复杂生物制品的可及性，同时加强区域和本地的生产能力。我们很自豪能够为这一联盟贡献我们的专业知识以及我们的疫苗和抗体生产技术，并在最重要的地方提供支持。”

said Dr. Volker Sandig, M.D., Chief Scientific Officer at ProBioGen.

普罗拜根公司首席科学官沃尔克·桑迪格博士说。

'Africa continues to face significant challenges in accessing monoclonal antibodies due to the lack of affordable, equitable, and sustainable supply. This partnership represents an important step forward in expanding access to mAbs and vaccines for the African continent. Africa CDC stands ready to support Member States in accessing these products through the African Pooled Procurement Mechanism (APPM),' .

“由于缺乏可负担、公平且可持续的供应，非洲在获取单克隆抗体方面仍然面临重大挑战。这一合作伙伴关系代表着扩大非洲大陆获取单克隆抗体和疫苗的重要一步。非洲疾控中心随时准备通过非洲联合采购机制（APPM）支持成员国获取这些产品。”

said H.E. Dr. Jean Kaseya, Director-General of the Africa Centres for Disease Control and Prevention (Africa CDC).

非洲疾病预防控制中心（Africa CDC）主任让·卡塞亚博士说。

For high resolution please click the image.

为了获得高分辨率，请点击图像。

About

关于

Minapharm Pharmaceuticals

米纳制药

Minapharm is a leading pharmaceutical company in Egypt and the Middle East and the premier biopharmaceutical company in Africa with over 25 years of experience in cellular and bioprocess engineering. Headquartered in Cairo, Minapharm commercializes over 100 life-saving and life-enhancing products ranging from small molecules to complex, genetically engineered proteins, with an impressive immunotherapy pipeline.

米纳制药是埃及和中东领先的制药公司，也是非洲首屈一指的生物制药公司，拥有超过25年在细胞和生物工艺工程方面的经验。总部位于开罗的米纳制药，商业化了100多种从小微分子到复杂的基因工程蛋白的救命和改善生命的药物，并拥有令人印象深刻的免疫治疗管线。

Together with its wholly-owned Berlin-based subsidiary, ProBioGen AG, a globally renowned CDMO and provider of innovative proprietary technologies in the fields of monoclonal antibodies, protein, viral, and cell therapies to the global biotech industry at large, Minapharm has established an integrated business model making it to date the only gene-to-market biopharmaceutical company in the region.

与全资子公司、总部位于柏林的ProBioGen AG共同合作，Minapharm建立了一个集成的业务模式，使其成为该地区迄今为止唯一的从基因到市场的生物制药公司。ProBioGen AG是全球知名的CDMO，为全球生物技术行业提供单克隆抗体、蛋白质、病毒和细胞疗法领域的创新专有技术供应商。

Minapharm employs a collective workforce of over 2,000 and is listed on the Cairo and Alexandria stock exchanges (Symbol: MIPH)..

Minapharm 拥有超过 2,000 名员工，并在开罗和亚历山大证券交易所上市（股票代码：MIPH）。

About

关于

ProBioGen

ProBioGen

ProBioGen is a Berlin-based specialist for developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines. The company applies proprietary technologies to enhance product quality and functionality across both recombinant protein therapeutics and complex virus-based modalities.

ProBioGen 是一家位于柏林的生物制药活性成分、病毒载体和疫苗开发与制造专家。该公司应用专有技术来提高重组蛋白治疗药物和复杂病毒模态产品的质量和功能。

Its integrated CDMO services span cell line and vector design, process development, GMP manufacturing, and advanced analytics – all embedded in a robust quality management system compliant with EMA/FDA standards. Platforms such as .

其综合CDMO服务涵盖细胞系和载体设计、工艺开发、GMP生产以及高级分析——所有这些都嵌入符合EMA/FDA标准的强大质量管理体系中。平台包括 。

CHO.RiGHT®

CHO.RiGHT®

for protein expression and

用于蛋白质表达和

AGE1.CR®

AGE1.CR®

cell lines for viral vector production enable clients to accelerate development while ensuring consistency and scalability. With nearly 300 employees at two Berlin sites and over 30 years of experience, ProBioGen supports partners worldwide in delivering the next generation of biologics and gene therapies.

用于病毒载体生产的细胞系使客户能够加快开发进程，同时确保一致性和可扩展性。ProBioGen在柏林的两个地点拥有近300名员工，并具备30多年的经验，支持全球合作伙伴交付下一代生物制品和基因疗法。

For more information about ProBioGen, follow us on .

欲了解有关ProBioGen的更多信息，请关注我们。

LinkedIn

领英

.

。

About

关于

IAVI

国际艾滋病疫苗行动组织

IAVI is a non-profit scientific research organization dedicated to addressing global, unmet health challenges including HIV and TB. Its mission is to translate scientific discoveries into affordable, globally accessible public health tools.

IAVI是一个非营利性科学研究组织，致力于应对全球未满足的健康挑战，包括艾滋病和结核病。其使命是将科学发现转化为价格合理的、全球可及的公共卫生工具。

Contacts

联系人

ProBioGen

ProBioGen

Sarah Wandrey

萨拉·万德雷

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

Minapharm

米纳制药

Christina Azmy

克里斯蒂娜·阿兹米

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到防垃圾邮件机器人的保护。您需要启用 JavaScript 才能查看它。

IAVI

国际艾滋病疫苗行动组织

Heather Teixeira

黛瑟·特谢拉

This email address is being protected from spambots. You need JavaScript enabled to view it.

该电子邮件地址正受到防垃圾邮件程序的保护。您需要启用 JavaScript 才能查看它。

Keywords: Manufacturing and Industrial Facilities; International Cooperation; Vaccine Development; Biological Products; Productivity; Technology; Bioreactors; Commerce; Germany; Afrika; Egypt; U.S.; IAVI; Minapharm; ProBioGen; Memorandum of Understanding; strategic partnership; biologics development; manufacturing; commercialization; vaccines; antibodies; Africa; Mpox; HIV; public-private partnership; local manufacturing; regional manufacturing hub; Africa Centres for Disease Control and Prevention (Africa CDC); Wellcome Trust; kENUP Africa Foundation; technology transfer; infectious diseases; vaccine vector technologies; product development; affordable biologics; sustainable access.

关键词：制造和工业设施；国际合作；疫苗开发；生物制品；生产力；技术；生物反应器；商业；德国；非洲；埃及；美国；IAVI；Minapharm；ProBioGen；谅解备忘录；战略伙伴关系；生物制品开发；制造；商业化；疫苗；抗体；非洲；Mpox；HIV；公私合作伙伴关系；本地制造；区域制造中心；非洲疾病控制和预防中心（Africa CDC）；惠康信托；kENUP非洲基金会；技术转让；传染病；疫苗载体技术；产品开发；可负担的生物制品；可持续获取。

Source: Biotech Newswire

来源：生物技术新闻社